Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by WalkOverTheStrton Jun 03, 2020 4:29pm
190 Views
Post# 31108614

RE:RE:Partnering ...

RE:RE:Partnering ...CyrolQue 
1) Your posts seem to try to stoke fear or come from a disgruntal position 
2) Your expectation of a full data set is naive and not cloaked in reality nor is how the ibdustry actuall operates....
3)  For your education.... botechs release initial results at a high level i.e. met or did not meet primary and some initial data. These companies then provide greater depth data sets / followed by peer reviewed submissions. Data sets take time to review and check, especially secondary end points that can be more obscure and require more analysis.  You are 100% obtuse on your expectation of a full data set at the inital PR or a few days afterwards. 
4) Whenever I read "unless..." I usually mute that person as it is a statement like "always" "must" and shows bias as well as ignorance. 


"unless they provide some hard & positive data tomorrow the share price will keep drifting lower and lower. Things being the way they are, even a good cc tomorrow won’t do much. The momentum is lost. It will take some hard work and a series of positive news for it to return. 
Bullboard Posts